Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Agency: Other Defense Agencies
State: Texas
Type of Government: Federal
FSC Category:
  • 65 - Medical, Dental, and Veterinary Equipment and Supplies
NAICS Category:
  • 325412 - Pharmaceutical Preparation Manufacturing
Posted Date: Jul 10, 2019
Due Date: Jul 31, 2019
Solicitation No: HT9402-19-Q-0005(3)
Bid Source: Please Login to View Page
Contact information: Please Login to View Page
Bid Documents: Please Login to View Page
Opportunity History
  • Original Synopsis
    Jul 10, 2019
    10:20 am
Solicitation Number :
HT9402-19-Q-0005(3)
Notice Type :
Combined Synopsis/Solicitation
Synopsis :
Added: Jul 10, 2019 10:20 am
Background:
The Department of Defense (DoD) is required by law (10 U.S.C. ยง 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: August 2019: The following drug classes/subclass and newly approved agents will be reviewed:

ADHD, SUB CLASS: Wakefulness Promoting Agents - Sunosi
Contraceptives, SUB CLASS: Progestogen Only - Slynd
Antilipidemics-1, SUB CLASS: NA - Ezallor
ADHD, SUB CLASS: Stimulants - Evekeo ODT
Migraine Agents, SUB CLASS: CGRP Cluster - Emgality
ADHD, SUB CLASS: Stimulants - Adhansia XR
Pulmonary 1-Agents, SUB CLASS: Pulmonary Miscellaneous - Nucala
Neurological Agents Miscellaneous, SUB CLASS: NA - Ruzurgi


RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.
There is no pre-proposal teleconference. Rather, questions shall be submitted via e-mail to the Request for Quote (RFQ) Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required.


POCs: Part 2.3 of the RFQ.
For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD

Please consult the list of document viewers if you cannot open a file.
RFQ Newly Approved Drugs
Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label:
RFQ Newly Approved Drugs
Posted Date:
July 10, 2019
Description: Solicitation for Newly Approved Drugs
Newly Approved Drug Appendices
Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label:
Newly Approved Drug Appendices
Posted Date:
July 10, 2019
NAD_Appendix3_-_Sunosi_-_ADHD_-_Wakefulness_Promotin... (31.27 Kb)
Download/View NAD_Appendix3_-_Sunosi_-_ADHD_-_Wakefulness_Promoting_Agents.docx
Description: NAD Appendix3 - Sunosi - ADHD - Wakefulness Promoting Agents
NAD_Appendix3_-_Slynd_-_Contraceptives_-_Progestogen... (31.07 Kb)
Download/View NAD_Appendix3_-_Slynd_-_Contraceptives_-_Progestogen_Only.docx
Description: NAD Appendix3 - Slynd - Contraceptives - Progestogen Only
NAD_Appendix3_-_Ezallor_-_Antilipidemics-1_-_NA.docx... (31.08 Kb)
Download/View NAD_Appendix3_-_Ezallor_-_Antilipidemics-1_-_NA.docx
Description: NAD Appendix3 - Ezallor - Antilipidemics-1 - NA
Description: NAD Appendix3 - Evekeo ODT - ADHD - Stimulants
NAD_Appendix3_-_Emgality_-_Migraine_Agents_-_CGRP_Cl... (31.30 Kb)
Download/View NAD_Appendix3_-_Emgality_-_Migraine_Agents_-_CGRP_Cluster.docx
Description: NAD Appendix3 - Emgality - Migraine Agents - CGRP Cluster
NAD_Appendix3_-_Adhansia_XR_-_ADHD_-_Stimulants.docx... (31.25 Kb)
Download/View NAD_Appendix3_-_Adhansia_XR_-_ADHD_-_Stimulants.docx
Description: NAD Appendix3 - Adhansia XR - ADHD - Stimulants
NAD_Appendix3_-_Nucala_-_Pulmonary_1-Agents_-_Pulmon... (31.21 Kb)
Download/View NAD_Appendix3_-_Nucala_-_Pulmonary_1-Agents_-_Pulmonary_Miscellaneous.docx
Description: NAD Appendix3 - Nucala - Pulmonary 1-Agents - Pulmonary Miscellaneous
NAD_Appendix3_-_Ruzurgi_-_Neurological_Agents_Miscel... (31.26 Kb)
Download/View NAD_Appendix3_-_Ruzurgi_-_Neurological_Agents_Miscellaneous_-_NA.docx
Description: NAD Appendix3 - Ruzurgi - Neurological Agents Miscellaneous - NA
Contracting Office Address :
16401 E. Centretech Pkwy
Aurora, Colorado 80011
United States
Place of Performance :
7800 IH-10 West, Ste 400
San Antonio, Texas 78230
United States
Primary Point of Contact. :
Alexia Ray,
Contract Analyst, CTR
Phone: 2105366020
Secondary Point of Contact :
Yvette H. Dluhos,
Contract Specialist
Phone: 210-536-6048
All Files
Newly Approved Drug Appendices
Jul 10, 2019
NAD_Appendix3_-_Suno...
Download/View NAD_Appendix3_-_Sunosi_-_ADHD_-_Wakefulness_Promoting_Agents.docx
NAD_Appendix3_-_Slyn...
Download/View NAD_Appendix3_-_Slynd_-_Contraceptives_-_Progestogen_Only.docx
NAD_Appendix3_-_Ezal...
Download/View NAD_Appendix3_-_Ezallor_-_Antilipidemics-1_-_NA.docx
NAD_Appendix3_-_Evek...
Download/View NAD_Appendix3_-_Evekeo_ODT_-_ADHD_-_Stimulants.docx
NAD_Appendix3_-_Emga...
Download/View NAD_Appendix3_-_Emgality_-_Migraine_Agents_-_CGRP_Cluster.docx
NAD_Appendix3_-_Adha...
Download/View NAD_Appendix3_-_Adhansia_XR_-_ADHD_-_Stimulants.docx
NAD_Appendix3_-_Nuca...
Download/View NAD_Appendix3_-_Nucala_-_Pulmonary_1-Agents_-_Pulmonary_Miscellaneous.docx
NAD_Appendix3_-_Ruzu...
Download/View NAD_Appendix3_-_Ruzurgi_-_Neurological_Agents_Miscellaneous_-_NA.docx
RFQ Newly Approved Drugs
Jul 10, 2019
RFQ__Newly_Approved_...
Download/View RFQ__Newly_Approved_Drugs.pdf
General Information
Notice Type:
Combined Synopsis/Solicitation
Posted Date:
July 10, 2019
Response Date:
Jul 31, 2019 12:00 pm Central
Archiving Policy:
Manual Archive
Archive Date:
-
Original Set Aside:
N/A
Set Aside:
N/A
Classification Code:
65 -- Medical, dental & veterinary equipment & supplies
NAICS Code:
325 -- Chemical Manufacturing/325412 -- Pharmaceutical Preparation Manufacturing

Related Document

Jul 15, 2019[Combined Synopsis/Solicitation] Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Sign-up for a Free Trial, Government Bid Alerts

With Free Trial, you can:

You will have a full access to bids, website, and receive daily bid report via email and web.

Try One Week FREE Now

See Also

Opportunity History Original Synopsis Jun 28, 2019 9:52 am Solicitation Number : 36C25619Q1099

Department of Veterans Affairs

Opportunity History Original Synopsis Jul 01, 2019 3:19 pm Solicitation Number : 36C25719Q1033

Department of Veterans Affairs

Opportunity History Complete View Original Synopsis Combined Synopsis/Solicitation May 28, 2019 9:24 am

Defense Logistics Agency

Opportunity History Complete View Original Synopsis Combined Synopsis/Solicitation Jun 17, 2019 8:27 am

Defense Logistics Agency